3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
10
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
16
Myelodysplastic Syndromes
12
Multiple Myeloma
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Hematologic Neoplasms
6
Neuroblastoma
5
Hodgkin Disease
5
Retinoblastoma
4
Lymphoma, Non-Hodgkin
4
Graft vs Host Disease
4
Anemia, Refractory, with Excess of Blasts
4
Myeloproliferative Disorders
3
Leukemia, Myelomonocytic, Chronic
3
Recurrence
2
Primary Myelofibrosis
2
Myelodysplastic-Myeloproliferative Diseases
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Biphenotypic, Acute
2
Leukemia, B-Cell
2
Leukemia
2
Ganglioneuroblastoma
2
Anemia, Aplastic
2
beta-Thalassemia
1
Venentoclax
1
Thrombocythemia, Essential
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Interventions
pembrolizumab
47
Specimen Handling
29
Magnetic Resonance Spectroscopy
25
Biopsy
25
Radiosurgery
17
Gemcitabine
17
Nivolumab
15
Paclitaxel
14
Cyclophosphamide
13
Cisplatin
13
Carboplatin
13
Bevacizumab
12
Drug Therapy
11
Taxes
10
Radiotherapy
10
Oxaliplatin
10
Leucovorin
10
Irinotecan
10
Fluorouracil
10
Capecitabine
10
trastuzumab deruxtecan
8
fludarabine
8
Pemetrexed
8
Doxorubicin
8
Cetuximab
8
cemiplimab
7
abemaciclib
7
Trastuzumab
7
Fulvestrant
7
Docetaxel
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm Metastasis
×
Melphalan
×
Clear all
NCT04150042
2026-01-29
SHARON
General Oncology, Inc.
Phase 1
Recruiting
24 enrolled